SynopsisPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer seeks to block Metsera's termination and ensure its own deal proceeds, having received early antitrust clearance. The legal battle highlights a competition for Metsera's promising obesity drug pipeline.
Pfizer Sues Merz and Novo Nordisk Over Deal Termination
Economic Times•
Full News
Share:
Disclaimer: This content has not been generated, created or edited by Achira News.
Publisher: Economic Times
Want to join the conversation?
Download our mobile app to comment, share your thoughts, and interact with other readers.